Many CML patients today are living with side effects so strong that their quality of life is greatly reduced, according to a survey by the CML Society of Canada.
GlaxoSmithKline's Volibris is a new endothelin receptor antagonist for the treatment of idiopathic (primary) pulmonary arterial hypertension, as well as PAH associated with connective tissue disease.
The euphemisms we use about death can mislead patients almost as much as telling kids that a fat guy in a red suit visits a billion homes in one night delivering wrapped, commercially available toys
